Treatment of MB07133 Plus Sintilimab in Patients With Hepatocellular Carcinoma
An open-label, multi-dose clinical trial design was used to investigate the combination of MB07133 injection combined with Sintilimab in the treatment of primary liver cancer in phase I/IIa studies, including two phases of dose escalation and dose expansion，in order to evaluate the safety and efficacy of MB07133 injection combined with Sintilimab.
Safety Issues|Efficacy|MTD
DRUG: Sintilimab 200mg+MB07133 600mg
Number of Participants with DLT Event, According to the internationally recognized NCI-CTCAE 5.0 toxicity evaluation standard, From initial administration to 21 days after starting administration|Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v5.0, All adverse medical events that occur after subjects receive the investigational product can be manifested as symptoms, signs, diseases, or laboratory abnormalities, but do not necessarily have a causal relationship with the investigational product., Starting to receive the experimental drug until 24 days after the last application|PFS, The time between the start of medication and the occurrence of objective tumor progression or death（RECIST1.1 ）, Screening period, every 2 cycles after starting treatment（each cycle is 21 days）until the date of first documented progression or date of death from any cause（No more than 24 cycles are expected）.
Area Under the Plasma Concentration Versus Time Curve (AUC) of Sintilimab, Pharmacokinetics of Sintilimab, Within 0.5 hours before infusion，0.5hour (± 5 min) after the start of infusion，4hour(±5min)、10hour(±5min)、25hour(±30min)、73hour(±30min)、170hour.|Area Under the Plasma Concentration Versus Time Curve (AUC) of MB07133, Pharmacokinetics of MB07133, Within 0.5 hours before infusion，0.5hour (± 5 min) after the start of infusion，1hour(± 5min)、2hour(±5min)、4hour(±5min)、8hour(±5min)、12hour(±5min)、23hour(±30min)、 47hour(±30min)、71hour(±30min)、119hour(±30min)、143hour(±30min)、168hour
An open-label, multi-dose clinical trial design was used to investigate the combination of MB07133 injection combined with Sintilimab in the treatment of primary liver cancer in phase I/IIa studies, including two phases of dose escalation and dose expansion，in order to evaluate the safety and efficacy of MB07133 injection combined with Sintilimab.